Top View
- 00747 Naxitamab
- Approved Drugs • on Aug. 5, the U.S. Food and Drug Administration (FDA
- Specialty Injectables Prior Authorization List
- Dinutuximab: a Newly Approved Immunotherapy for the Treatment of Neuroblastoma
- DANYELZA (Naxitamab-Gqgk) Label
- Danyelza® (Naxitamab-Gqgk) (Intravenous) Document Number: IC-0581 Last Review Date: 01/05/2021 Date of Origin: 01/05/2021 Dates Reviewed: 01/2021
- Oncology Medications Policy (1403)
- CY 2020 CDER New Molecular Entity (NME) Drug & Original BLA Calendar Year Approvals As of Decemeber 31, 2020
- Master Precertification List
- Naxitamab-Gqgk (Danyelza®)
- Preliminary Tolerability Assessment of Naxitamab (Humanized Anti-GD2 Monoclonal Antibody) Therapy in a Phase 2 Osteosarcoma Trial
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- TAG Mail – 17 Dec 2020
- New Oncology & Hematology Prior Authorization Program for Medicare
- Announced That the US Food and Drug Administration
- Antibody News You Should Know July 1 - 15, 2020
- Specialty Pipeline Monthly Update June 2021
- Specialty Pipeline MONTHLY UPDATE
- Prior Authorization — Premium
- Antibodies to Watch in a Pandemic
- Oncology Medications and Supportive Agents Require Review by New
- 2020 FDA Drug Approvals Priority Reviews, for Products That Would the FDA Approved 53 Novel Drugs in 2020, the Second Highest Count in Over 20 Years
- Antibodies to Watch in 2020
- Pipeline Report
- The Pharmaceutical Industry in 2020. an Analysis of FDA Drug Approvals from the Perspective of Molecules
- Drugs Billed Under Miscellaneous Codes J3490, J3590, J9999 Or C9399 Prior Authorization Coverage Information
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- Therapeutic Monoclonal Antibodies Approved by FDA in 2020 Henry Hongrong Cai, MD
- P&T Committee Meeting Minutes Medicare February 23, 2021 E-Vote DRUG REVIEWS DANYELZA